Korro Bio Inc.
KRRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$103.22M
Close$
$-5.59
149.2% downside
Current Fair Value
149.2% downsideOvervalued by 149.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $103.22 Million |
|---|---|
| Enterprise Value | $84.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.48 |
| Beta | 2.11 |
| Outstanding Shares | 11,598,717 |
Return
| Return on Equity | -94.87% |
|---|---|
| Return on Assets | -61.81% |
| Return on Invested Capital | -69.47% |
Valuation & Multiples
| P/E Ratio | -0.89 |
|---|---|
| PEG | 5.52 |
| Price to Sales | - |
| Price to Book Ratio | 1.14 |
| Enterprise Value to Revenue | 22.02 |
| Enterprise Value to EBIT | -0.72 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-1.73
Average shareholder expectationRevenue Estimate
$761,167
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-1.34
Average shareholder expectationRevenue Estimate
$214,286
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 209.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 110.11% |
|---|---|
| Total Invested | $414,657▼ 99.71% |
| Investors Holding | 17▼ 87.00% |
ESG Score
No data
About Korro Bio Inc.
66 employeesfrequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the comp...